Roadmap to Implementation of a Rapid “Lab in a Pouch” NAT Method for Mycoplasma Testing

Mycoplasma testing is a mandatory assay for all cell-derived products as part of the microbial control strategy. The compendial methods include an indicator cell culture method and a culture assay. Because the culture assay takes 28 days, the time-to-result (TTR) is one of the longest in the microbiology laboratory. Besides this, the compendial Mycoplasma methods are highly complex, subjective, and need strict segregation of labs to avoid cross-contamination with Mycoplasma. The pharmaceutical industry is seeking faster solutions, like nucleic acid testing (NAT)-based methods. There are alternative and rapid NAT methods on the market enabling a reduction of the TTR to approximately 1 day (1). Although some of these NAT methods offer partial automated solutions (e.g., nucleic acid extraction), many of them still require strict separation of test areas to avoid false-positive results and provide only limited hands-on-time reduction and simplification. In contrast, the BioFire® Filmarray® technology is a NAT method that is easy to use thanks to a closed process-a so called "lab in a pouch"-and provides the result within only 2 hours, including sample preparation. Besides the risk reduction of human errors due to the limited manual work involved, the automation can also lead to improved data integrity compared to the compendial method. This paper describes the roadmap of implementation of the BioFire<sup>®</sup> Filmarray<sup>®</sup> technology. The approach from feasibility studies to validation and regulatory submission for a monoclonal antibody (mAb)-based product is provided. As a first, J&J received regulatory approval from several agencies (including the US FDA and the EMA) to apply this technology for a biopharmaceutical product and has started global roll-out to additional products and testing sites. Understanding the risk concomitant with introducing new methods is essential to develop an appropriate validation, implementation, and filing strategy. The process applied at J&J for the first product will be shared in this publication.

Authors

Institutions

Publication Details

Journal
PDA Journal of Pharmaceutical Science and Technology
Published
2025-08-28
DOI
https://doi.org/10.5731/pdajpst.2024-003022.1
Primary Topic
Microbial infections and disease research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Roadmap to Implementation of a Rapid “Lab in a Pouch” NAT Method for Mycoplasma Testing

Philip Breugelmans, Karen de Roy, Orm Nieuwenhuizen, Heike Merget-Millitzer
PDA Journal of Pharmaceutical Science and Technology
Microbial infections and disease research
article

Roadmap to Implementation of a Rapid “Lab in a Pouch” NAT Method for Mycoplasma Testing

Philip Breugelmans, Karen de Roy, Orm Nieuwenhuizen, Heike Merget-Millitzer
article en

Abstract

Mycoplasma testing is a mandatory assay for all cell-derived products as part of the microbial control strategy. The compendial methods include an indicator cell culture method and a culture assay. Because the culture assay takes 28 days, the time-to-result (TTR) is one of the longest in the microbiology laboratory. Besides this, the compendial Mycoplasma methods are highly complex, subjective, and need strict segregation of labs to avoid cross-contamination with Mycoplasma. The pharmaceutical industry is seeking faster solutions, like nucleic acid testing (NAT)-based methods. There are alternative and rapid NAT methods on the market enabling a reduction of the TTR to approximately 1 day (1). Although some of these NAT methods offer partial automated solutions (e.g., nucleic acid extraction), many of them still require strict separation of test areas to avoid false-positive results and provide only limited hands-on-time reduction and simplification. In contrast, the BioFire® Filmarray® technology is a NAT method that is easy to use thanks to a closed process-a so called "lab in a pouch"-and provides the result within only 2 hours, including sample preparation. Besides the risk reduction of human errors due to the limited manual work involved, the automation can also lead to improved data integrity compared to the compendial method. This paper describes the roadmap of implementation of the BioFire<sup>®</sup> Filmarray<sup>®</sup> technology. The approach from feasibility studies to validation and regulatory submission for a monoclonal antibody (mAb)-based product is provided. As a first, J&J received regulatory approval from several agencies (including the US FDA and the EMA) to apply this technology for a biopharmaceutical product and has started global roll-out to additional products and testing sites. Understanding the risk concomitant with introducing new methods is essential to develop an appropriate validation, implementation, and filing strategy. The process applied at J&J for the first product will be shared in this publication.

PDA Journal of Pharmaceutical Science and TechnologyVol. 79(5)
Johnson & Johnson (United States) (US), Janssen (Belgium) (BE)
Openalex Percentile: Top 79%
Microbial infections and disease research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.